RxSight Q2 adjusted loss beats estimates; withdraws 2026 guidance
RXST•Outlook
The company withdrew 2026 guidance and said it will resume formal guidance in early 2027.
Earnings and expense details
Adjusted loss per share for Q2 beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Adjusted Loss Per Share | Beat | $0.11 | $0.33 (10 Analysts) |
| Q2 Loss Per Share | $0.29 | ||
| Q2 Adjusted Net Loss | $4.63 mln | ||
| Q2 Operating Expenses | $39.70 mln |
Q2 results and revenue drivers
US ophthalmic device maker RxSight reported second-quarter revenue of $33.7 million, including $6.5 million from its Alcon collaboration.
Q2 product sales fell 19% year over year due to heightened competition and weak consumer sentiment.
Analyst coverage and peer context
The current average analyst rating on the shares is hold, with a breakdown of 1 strong buy or buy, , and .
Related News
DHT Q2 FY26 profit rises 253.9% to USD 198.3 million; revenue more than doubles to USD 284.8 million
DHT•
CF Industries misses second-quarter estimates as lower volumes offset higher fertilizer prices
CF•
